Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Genitourinary 1Endocrine 1Classical hematology 1CNS 1

Conditions

Keratosis, Actinic 2

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Solutions × Dermatologic × Clear all
NCT03024060 2017-11-07

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

DUSA Pharmaceuticals, Inc.

Phase 3 Withdrawn
Dermatologic

Keratosis, Actinic

NCT02137785 2015-09-16

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

DUSA Pharmaceuticals, Inc.

Phase 3 Completed
269 enrolled 61 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡